GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (OTCPK:ONCSQ) » Definitions » Shiller PE Ratio

OncoSec Medical (OncoSec Medical) Shiller PE Ratio : (As of May. 16, 2024)


View and export this data going back to 1986. Start your Free Trial

What is OncoSec Medical Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


OncoSec Medical Shiller PE Ratio Historical Data

The historical data trend for OncoSec Medical's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Shiller PE Ratio Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OncoSec Medical's Shiller PE Ratio

For the Biotechnology subindustry, OncoSec Medical's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSec Medical's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's Shiller PE Ratio falls into.



OncoSec Medical Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

OncoSec Medical's E10 for the quarter that ended in Jan. 2023 is calculated as:

For example, OncoSec Medical's adjusted earnings per share data for the three months ended in Jan. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jan. 2023 (Change)*Current CPI (Jan. 2023)
=-2.65/126.2230*126.2230
=-2.650

Current CPI (Jan. 2023) = 126.2230.

OncoSec Medical Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201304 -44.000 98.107 -56.610
201307 -74.800 98.557 -95.798
201310 -44.000 98.536 -56.364
201401 -44.000 98.692 -56.274
201404 -81.400 100.023 -102.722
201407 -66.000 100.520 -82.876
201410 -72.600 100.176 -91.477
201501 -83.600 98.604 -107.017
201504 -105.600 99.824 -133.527
201507 -105.600 100.691 -132.377
201510 -103.400 100.346 -130.064
201601 -92.400 99.957 -116.680
201604 -81.400 100.947 -101.782
201607 -79.200 101.524 -98.468
201610 -63.800 101.988 -78.961
201701 -59.400 102.456 -73.179
201704 -48.400 103.167 -59.216
201707 -59.400 103.278 -72.597
201710 -57.200 104.070 -69.376
201801 -68.200 104.578 -82.316
201804 -43.560 105.708 -52.014
201807 -50.380 106.324 -59.809
201810 -30.140 106.695 -35.656
201901 -29.260 106.200 -34.777
201904 -22.660 107.818 -26.528
201907 -12.760 108.250 -14.879
201910 -20.240 108.577 -23.529
202001 -27.940 108.841 -32.402
202004 -9.900 108.173 -11.552
202007 -5.500 109.318 -6.351
202010 -10.780 109.861 -12.386
202101 -8.140 110.364 -9.310
202104 -5.500 112.673 -6.161
202107 -6.380 115.183 -6.992
202110 -5.516 116.696 -5.966
202201 -5.540 118.619 -5.895
202204 -3.520 121.978 -3.642
202207 -4.620 125.002 -4.665
202210 -4.505 125.734 -4.523
202301 -2.650 126.223 -2.650

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


OncoSec Medical  (OTCPK:ONCSQ) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


OncoSec Medical Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSec Medical (OncoSec Medical) Business Description

Traded in Other Exchanges
N/A
Address
24 North Main Street, Pennington, NJ, USA, 08534
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.
Executives
Robert J Delaversano officer: Principal Accounting Officer 217 W. MAIN STREET, SOMERVILLE NJ 08876
Spahr Stephany Foster director C/O ONCOSEC MEDICAL, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Robert H. Arch officer: President and CEO C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
George Chi officer: Chief Financial Officer 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Lin Shi director 24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218
Margaret Dalesandro director ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Yuhang Zhao director 6 HORTON DR., CHESTER NJ 07930
Brian A Leuthner officer: Chief Operating Officer 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Daniel J. O'connor director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
China Grand Pharmaceutical & Healthcare Holdings Ltd 10 percent owner, other: See Remarks UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000
Alpha Holdings, Inc. director, 10 percent owner GANGNAM-GU APGUJEONG-RO 62-GIL 17-10, SEOUL M5 06016
Kellie Malloy Foerter officer: Chief Operating Officer C/O ONCOSEC MEDICAL INCORPORATED, 24 N. MAIN STREET, PENNINGTON NJ 08534-2218
Herbert Kim Lyerly director C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218
Chao Zhou director UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000
Grand Decade Developments Ltd 10 percent owner, other: See Remarks UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000